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PATIENT CHARACTERISTICS
Total Unmanipulated TNC/kg x 10^7 6.2 (4.3 to 17)
Total Unmanipulated CD34/kg x 10^6 0.3 (0.09 to 1)
Expanded Product TNC/kg x 10^7 5.8 (2.2 to 10)
Expanded Product CD34/kg x 10^6 6 (3.1 to 11)
*HLA matching reflects the lowest HLA-match of the 2 unmanipulated
units.4
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With the goal of overcoming the significant delay in ANC re-
covery following cord blood transplantation (CBT), we have de-
veloped a clinically feasible methodology utilizing Notch ligand
for ex vivo generation of increased numbers of CD34+ cells.
Having previously demonstrated a significant reduction in ANC
recovery time in patients receiving these partially HLA-matched
expanded cells in a myeloablative CBT, we are now evaluating
whether this product could also support rapid myeloid recovery
when used as a non-HLA matched, off-the-shelf product. In
this new pilot study, patients undergo single or double ablative
CBT plus infusion of progenitors that have been previously ex-
panded from a fresh CB unit and then cryopreserved for future
use. To date, 13 patients have been enrolled (see Table for pa-
tient/graft characteristics). Importantly, no infusional toxicities
have been observed and no serious adverse events have been at-
tributed to the expansion product. All (n 5 11) patients have en-
grafted, with 2 being too early post transplant to evaluate.
Median time to achieve an ANC of 100/ml and 500/ml was 11
(range 7 to 20) and 19 days (range 9 to 28), respectively as com-
pared to 19 (range 11 to 37) (p 5 0.0001) and 25 days (range 14
to 45) (p 5 0.004) in a concurrent cohort of patients receiving
ablative double CBT without the expanded cells. Donor(s)/host
chimerism studies were performed weekly from day 7 to 28 on
peripheral blood flow sorted into myeloid and lymphoid frac-
tions. Similar to our initial expansion trial using partially HLA-
matched expanded CB cells, early (day 7) myelomonocytic
(CD33 and CD14) recovery is almost entirely (98–100%) due
to cells arising from the expansion product. Cells derived from
the expansion product are no longer detected at day 14 in all
but 2 patients, which is similar to our previous trial in whichTable. Unit and Patient Characteristics Total Enrolled N5 13
PATIENT CHARACTERISTICS
Gender, No (%)
Male 7 (54%)
Female 6 (46%)
Age in years, median (range) 22 (5 to 45)
Weight in kilograms, median (range) 67 (22 to 84)
Diagnosis, No (%)
ALL 6 (46%)
AML 6 (46%)
MDS 1 (8%)
Follow-up in days, median (range) 180 (16 to 385)
UNIT CHARACTERISTICS
Number of Unmanipulated Donors, No (%)
1 2 (15%)
2 11 (85%)
HLA match unmanipulated Donors, No (%)*
4/6 8 (62%)
5/6 5 (38%)
Infused Cell Doses (pre-freeze)
(Continued )contribution to donor engraftment in any cell fraction from the
expanded unit was no longer detected by day 14 in half of the
patients and only two patients had persistence of the expanded
cells beyond day 21. Of note, the expanded cells have not been
associated with increased incidence or severity of acute GVHD
or with development of alloimmunization. All patients are alive;
one patient with relapsed disease at the start of conditioning is
being treated for post transplant relapse. These promising results
warrant evaluation in a randomized phase II study to assess clin-
ical efficacy of this non-HLA matched, off-the-shelf expansion
product.5
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Introduction: CMX001, an oral Lipid-Antiviral-Conjugate, gener-
ates high intracellular levels of cidofovir-diphosphate. CMX001 has
potent in vitro activity against dsDNA viruses including herpesvi-
ruses, adenoviruses, polyomaviruses, and orthopoxviruses. Patients
treated for these infections under individual EIND protocols experi-
enced reductions in virus loads following CMX001 treatment; how-
ever, controlled human safety and efficacy data were previously not
available.
Methods: This randomized, placebo-controlled, dose-escalation
study (CMX001-201) enrolled adult allogeneic CMV-seropositive
stem-cell transplant (SCT) recipients from 27 centers in USA. Pa-
tients, stratified post-engraftment by acute GVHD requiring sys-
temic glucocorticoid therapy or CMV viremia, were randomized
(3:1) to receive CMX001 or placebo into 5 sequential dose-escalating
cohorts. Subjects were treated either once weekly (QW) or twice
weekly (BIW) for 9 to 11 weeks until Week 13 post-transplant
with a 4 to 8 week safety follow-up period. Virology and safety as-
sessments were conducted weekly throughout the treatment period.
A DSMB reviewed safety data and directed CMX001 doses for each
cohort. Efficacy was measured by a composite endpoint of CMV dis-
ease or the appearance/progression of CMV viremia. Patients with
these endpoints discontinued study drug and received anti-CMV
treatment. This study was registered with ClinicalTrials.gov,
NCT00942305.S203
